Comorbidity in Small Cell Lung Cancer: Prognostic Impacts of Hypertension/Coronary Artery Disease, Diabetes Mellitus, and Chronic Obstructive Pulmonary Disease.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-01-01 Epub Date: 2024-02-01 DOI:10.1080/07357907.2024.2310574

Faruk Tas, Akin Ozturk, Kayhan Erturk

引用次数: 0

Abstract

Comorbidity, the most important components of which are hypertension/coronary artery disease (HTN/CAD), diabetes mellitus (DM), and chronic obstructive pulmonary disease (COPD), is frequently encountered in small cell lung cancer (SCLC) patients. We aimed to assess the possible impacts of these major comorbidities on the prognoses of SCLC patients. A total of 378 SCLC patients were analyzed retrospectively. We did not ascertain the effect of comorbidity on survival in SCLC patients in general; and similarly, the presence of HTN/CAD and COPD did not adversely affect the outcome. However, lower survival rates were observed in patients with SCLC coexisting with DM.

查看原文本刊更多论文

小细胞肺癌的合并症：高血压/冠状动脉疾病、糖尿病和慢性阻塞性肺病的预后影响。

合并症是小细胞肺癌（SCLC）患者的常见病，其中最重要的组成部分是高血压/冠状动脉疾病（HTN/CAD）、糖尿病（DM）和慢性阻塞性肺疾病（COPD）。我们旨在评估这些主要合并症对 SCLC 患者预后可能产生的影响。我们对 378 名 SCLC 患者进行了回顾性分析。我们没有确定合并症对一般 SCLC 患者生存率的影响；同样，存在高血压/冠心病和慢性阻塞性肺病也不会对预后产生不利影响。然而，我们观察到，SCLC 患者同时患有糖尿病的存活率较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.